Step by Step


ABIM MOC Activity ID

1/23/2018 - Medical Grand Rounds: Strategies to Enhance the Efficacy of CAR T Cells





Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Describe the principles of synthetic biology in T cell therapy of cancer.
  • Discuss safety and efficacy of chimeric antigen receptor modified T cells for B cell malignancies.
  • Define the mechanisms of tumor escape from T cell immunotherapies

Stanley Riddell, MD — Fred Hutchinson Cancer Research Center, University of Washington American Cancer Society Virginia Hobbs Charitable Trust Research Professor
Dr. Riddell receives grant/research support from Juno Therapeutics. He is consultant for Juno Therapeutics, Adaptive Biotechnologies, Cell Medica, NOHLA. He is a stockholder in Juno Theapeutics.
Authors disclosure of relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients is listed above. No other planners, members of the planning committee, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Pittsburgh School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits. Each physician should only claim credit commensurate with the extent of their participation in the activity.

The University of Pittsburgh is an affirmative action, equal opportunity institution.